Does raising threshold for diagnosis of polycystic ovary syndrome exclude population of patients with metabolic risk?
The women excluded from the PCOS diagnosis by raising the threshold of follicle number per ovary to ≥25 continue to show evidence of metabolic risk.
Risk analysis of the effect of pramlintide treatment demonstrated risk-reduction effects independent of changes in average glycemia, most notably reduced rate and magnitude of postprandial BG fluctuations. These effects were not accompanied by an increased risk of hypoglycemia.